Compare · ACHV vs AKER
ACHV vs AKER
Side-by-side comparison of Achieve Life Sciences Inc. (ACHV) and Akers Biosciences Inc. (AKER): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACHV and AKER operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ACHV carries a market cap of $697.7M.
- ACHV has hit the wire 5 times in the past 4 weeks while AKER has been quiet.
- ACHV has more recent analyst coverage (11 ratings vs 0 for AKER).
- Company
- Achieve Life Sciences Inc.
- Akers Biosciences Inc.
- Price
- -
- -
- Market cap
- $697.7M
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 5
- 0
- Recent ratings
- 11
- 0
ACHV
Achieve Life Sciences Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Latest ACHV
- SEC Form 10-Q filed by Achieve Life Sciences Inc.
- Achieve Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AchieveRx Reports Third Quarter 2026 Financial Results and Provides Business Updates
- Achieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUIT
- Achieve Life Sciences Announces Granting of New Hire Inducement Awards
- Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
- Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
- Achieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and Communications
- SEC Form 4 filed by Achieve Life Sciences Inc.
- SEC Form 3 filed by Achieve Life Sciences Inc.
Latest AKER
- SEC Form S-3/A filed by Akers Biosciences Inc. (Amendment)
- SEC Form 3: Williams Caroline C claimed ownership of 5,017,423 units of Common Stock
- SEC Form 4 filed by EAGLE CRAIG
- SEC Form 3 filed by EAGLE CRAIG
- Akers Biosciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 4 filed by Kaplin Adam
- SEC Form 3 filed by Kaplin Adam
- SEC Form 4: Schreiber Christopher C exercised 131,750 units of Common Stock at a strike of $0.00 and disposed of $227,798 worth of Common Stock (46,113 units at $4.94), increasing direct ownership by 3,292% to 88,238 units to cover withholding tax
- SEC Form 4 filed by Uzonwanne Jude
- SEC Form 4: Chapman Christopher C JR was granted 96,475 units of Common Stock